

Drug Screening Market by Offering (On-site Testing, Rapid Testing (Urine, Oral), Analytical (Breathalyzer, Immunoassay, Chromatography)), Sample (Blood, Urine, Hair), Drug (Cannabis, Alcohol), End User (Workplace, Law, Hospitals) - Global Forecast to 2030

Market Report | 2026-02-13 | 456 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global drug screening market is projected to reach USD 21.29 billion by 2030 from USD 10.36 billion in 2025, at a CAGR of 15.5%. The drug screening market is being driven by expanding government mandates and risk-based testing across safety-sensitive sectors such as transportation, construction, and manufacturing. This growth is underpinned by rising global substance use. Around 316 million people worldwide used drugs in 2023, a rate increasing faster than population growth, heightening impairment risks in workplaces and on public roads. Drug-related impairment is a critical contributor to road traffic injuries (RTIs), which cause approximately 1.3 million deaths annually, with 93% occurring in low- and middle-income countries, reinforcing the need for roadside and post-incident drug testing programs globally. In the US, post-accident workplace drug positivity reached 10.4% in 2023, with marijuana positivity rising to a 25-year high of 7.5%, illustrating similar risk patterns in mature markets and accelerating adoption of random and post-incident testing. As a result, employers and regulators are prioritizing fast, legally defensible screening and confirmatory solutions, while hospitals increasingly rely on high-throughput LC-MS definitive toxicology testing to support critical clinical decisions. At the same time, broader acceptance of oral fluid, saliva, and hair testing is reshaping testing protocols by enabling more accurate detection of recent drug use with lower tampering risk, compelling organizations to upgrade conventional drug screening technologies in response to rising impairment rates and stricter accreditation standards.

<https://mnmimg.marketsandmarkets.com/Images/drug-alcohol-screening-market-img-overview.webp>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

"By offering, services segment to account for largest market share"

Based on offering, the services segment, which includes laboratory testing services and onsite testing services, is anticipated to fuel the drug screening market over the forecast period, as organizations continue to adopt comprehensive and managed testing services. Laboratory testing services assist in dealing with a large number of tests, confirmatory tests, and regulatory requirements, whereas onsite testing services facilitate rapid testing at the point of need. The rising trend of compliance-driven, random, and multi-panel testing programs, as well as the increasing use of alternative specimen types such as oral fluid and hair, is driving the demand for specialized service providers. This is also evident in the operational trends, which highlight that, according to the 2023 Quest Diagnostics Drug Testing Index, incidents of workforce test cheating jumped sharply, indicating the growing complexity and need for expert management and confirmatory services. In addition, workplace trends in 2025 highlight that scalability, regulatory compliance, and integrated reporting are key drivers for organizations outsourcing drug testing, rather than managing testing programs in-house. As testing volumes and expenses increase, organizations are increasingly adopting scalable, compliant, and service-oriented drug screening solutions, which support robust growth in the services market. In December 2022, Omega Laboratories launched the Urine Drugs of Abuse Testing Services in its state-of-the-art laboratory in Ontario, Canada. The laboratory offered urine drug testing from January 3, 2023, to complement its molecular testing.

"By end user, drug testing laboratories accounted for largest share of drug screening market in 2024."

The global drug screening market is fueled by the growing prevalence of illicit drug use, occupational health and safety concerns, and changing medical and legal needs. Globally, it is estimated that 9% of the adult population between 15 and 64 years of age uses illicit drugs every year, with cannabis, opioids, and stimulants being the most prevalent, while drug-related deaths contribute to approximately 0.6 million deaths annually, emphasizing a substantial public health problem. In Europe, cannabis use is a problem for 8.4% of adults, and drug-related deaths continue to increase, largely due to opioids and polysubstance use. These factors are fueling increasing post-incident, random, and routine drug screening in the workplace in safety-sensitive industries worldwide. The increasing use of non-invasive specimen types, such as oral fluid and hair, as well as the expansion of roadside and law enforcement drug testing, is improving the detection of recent drug use and preventing sample tampering.

"APAC to witness the highest growth rate during the forecast period"

The increasing prevalence of substance use and the structural need for outsourced laboratory testing are driving the market in Asia Pacific. In Australia, the 2022-2023 National Drug Strategy Household Survey estimates that 1.8 million people smoke daily, 2.5 million people have used cannabis in the past 12 months, 1.0 million people have used cocaine, and 6.6 million people engage in risky alcohol consumption, reflecting the continued demand for clinical toxicology and substance monitoring services in healthcare and occupational settings. Moreover, illicit substance use, including cocaine and e-cigarettes, is rising among young adults and women, expanding the tested population beyond the traditional high-risk group. In India, the numbers are even more substantial. National survey data show that 14.6% of the population (approximately 160 million people) are current alcohol users, 31 million people use cannabis, and over 20 million people use opioids, with nearly 6 million people in need of treatment services. Furthermore, 11.8 million people misuse sedatives, and an estimated 850,000 people inject drugs, representing a continued need for laboratory-based toxicology testing in hospitals, rehabilitation facilities, and public health settings.

The breakdown of primary participants is as given below:

-□By Company Type - Tier 1: 60%, Tier 2: 30%, and Tier 3: 10%

-□By Designation - C-level: 30%, Director-level: 50%, and Others: 20%

-□By Region - North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the world: 10%.

Labcorp (US), Quest Diagnostics Incorporated (US), and Abbott (US) are some of the key players in the drug screening market.

-□The study includes an in-depth competitive analysis of these key players in the drug screening market, with their company profiles, recent developments, and key market strategies.

Research Coverage

This research report categorizes the drug screening market by offering (products & services), sample type (urine samples, breath samples, oral fluid samples, hair samples, other samples), drug type (cannabis, alcohol, cocaine, opioids, amphetamine and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

methamphetamine, other drugs) end user (drug testing laboratories, workplaces, criminal justice systems and law enforcement agencies, hospitals, drug treatment centers, individual users, pain management centers, schools and colleges, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the drug screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions, and recent developments associated with the drug screening market. Competitive analysis of upcoming startups in the drug screening market ecosystem is covered in this report.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the drug screening market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

- Analysis of key drivers (Growing consumption of illicit drugs and alcohol, Enforcement of stringent laws mandating drug and alcohol testing, Increasing number of regulatory approvals for drug screening products and services) restraints (Ban on alcohol consumption in Islamic countries, Prohibition on workplace drug testing) opportunities (Popularity of oral fluid testing, Introduction of fingerprint-based drug testing at workplaces, High growth opportunities in emerging economies) challenges (Accuracy and specificity concerns in breathalyzers, False positive and negative results in drug screening) influencing the growth of the drug screening market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the drug screening market
- Market Development: Comprehensive information about lucrative markets; the report analyses the drug screening market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the drug screening market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like LabCorp (US), Quest Diagnostics Incorporated (US), Abbott (US), OraSure Technologies Inc. (US), Alfa Scientific Designs Inc. (US), Thermo Fisher Scientific Inc. (US), and Drägerwerk AG & Co. KGaA (Germany), among others, in the drug screening market

Table of Contents:

1	INTRODUCTION	39
1.1	STUDY OBJECTIVES	39
1.2	MARKET DEFINITION	39
1.3	MARKET SCOPE	40
1.3.1	MARKET SEGMENTATION & REGIONAL SCOPE	40
1.3.2	INCLUSIONS & EXCLUSIONS	41
1.3.3	YEARS CONSIDERED	42
1.4	CURRENCY CONSIDERED	42
1.5	LIMITATIONS	43
1.6	STAKEHOLDERS	43
1.7	SUMMARY OF CHANGES	44
2	EXECUTIVE SUMMARY	45
2.1	MARKET HIGHLIGHTS & KEY INSIGHTS	45
2.2	KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS	46
2.3	DISRUPTIVE TRENDS IN DRUG SCREENING MARKET	47

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.4	HIGH-GROWTH SEGMENTS	48
2.5	REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST	49
3	PREMIUM INSIGHTS	50
3.1	DRUG SCREENING MARKET OVERVIEW	50
3.2	DRUG SCREENING MARKET, BY OFFERING & REGION	51
3.3	DRUG SCREENING MARKET: GEOGRAPHIC SNAPSHOT	52
3.4	DRUG SCREENING MARKET: DEVELOPED VS. EMERGING ECONOMIES	52
4	MARKET OVERVIEW	53
4.1	INTRODUCTION	53
4.2	MARKET DYNAMICS	54
4.2.1	DRIVERS	54
4.2.1.1	Growing consumption of illicit drugs and alcohol	54
4.2.1.2	Enforcement of stringent laws mandating drug and alcohol testing	55
4.2.1.3	Increasing number of regulatory approvals for drug screening products & services	56
4.2.2	RESTRAINTS	57
4.2.2.1	Ban on alcohol consumption in Islamic countries	57
4.2.2.2	Prohibition on workplace drug testing	57
4.2.3	OPPORTUNITIES	58
4.2.3.1	Popularity of oral fluid testing	58
4.2.3.2	Introduction of fingerprint-based drug testing in workplaces	58
4.2.3.3	High growth opportunities in emerging economies	59
4.2.4	CHALLENGES	59
4.2.4.1	Accuracy and specificity concerns in breathalyzers	59
4.2.4.2	False positive and negative results in drug screening	60
4.3	UNMET NEEDS & WHITE SPACES	60
4.4	INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES	61
4.5	STRATEGIC MOVES BY TIER-1/2/3 PLAYERS	61
5	INDUSTRY TRENDS	63
5.1	PORTER'S FIVE FORCES ANALYSIS	63
5.1.1	BARGAINING POWER OF SUPPLIERS	64
5.1.2	BARGAINING POWER OF BUYERS	64
5.1.3	THREAT OF SUBSTITUTES	64
5.1.4	THREAT OF NEW ENTRANTS	65
5.1.5	INTENSITY OF COMPETITIVE RIVALRY	65
5.2	MACROECONOMIC INDICATORS	65
5.2.1	INTRODUCTION	65
5.2.2	GDP TRENDS & FORECAST	65
5.2.3	TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY	66
5.3	VALUE CHAIN ANALYSIS	66
5.4	ECOSYSTEM ANALYSIS	68
5.5	PRICING ANALYSIS	70
5.5.1	INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES, BY TYPE (2024)	70
5.5.2	INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES, BY REGION (2024)	71
5.6	KEY CONFERENCES & EVENTS, 2026-2027	71
5.7	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	72

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.8	INVESTMENT & FUNDING SCENARIO	73
5.9	CASE STUDY ANALYSIS	74
5.10	IMPACT OF 2025 US TARIFFS ON DRUG SCREENING MARKET	76
5.10.1	INTRODUCTION	76
5.10.2	KEY TARIFF RATES	76
5.10.3	PRICE IMPACT ANALYSIS	77
5.10.4	IMPACT ON COUNTRY/REGION	77
5.10.4.1	US	77
5.10.4.2	Europe	78
5.10.4.3	Asia Pacific	79
5.10.5	IMPACT ON END-USE INDUSTRIES	79
5.10.5.1	Drug testing laboratories	79
5.10.5.2	Workplaces	79
5.10.5.3	Criminal justice systems & law enforcement agencies	80
5.10.5.4	Hospitals	80
5.10.5.5	Drug treatment centers	80
5.10.5.6	Individual users	80
5.10.5.7	Pain management centers	80
5.10.5.8	Schools & colleges	80
5.10.5.9	Other end users	81
6	STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION	82
6.1	KEY EMERGING TECHNOLOGIES	82
6.1.1	LC-MS/MS & GC-MS-BASED CONFIRMATORY TESTING TECHNOLOGIES	82
6.1.2	AI-DRIVEN RESULT INTERPRETATION & QUALITY ASSURANCE TECHNOLOGIES	82
6.1.3	LABORATORY AUTOMATION & ROBOTICS TECHNOLOGIES	83
6.2	COMPLEMENTARY TECHNOLOGIES	83
6.2.1	MOBILE HEALTH (MHEALTH) & REMOTE COLLECTION TECHNOLOGIES	83
6.2.2	ANALYTICS & POPULATION-LEVEL DRUG USE SURVEILLANCE TOOLS	84
6.3	ADJACENT TECHNOLOGIES	84
6.3.1	FORENSIC CASE MANAGEMENT SYSTEMS	84
6.3.2	WORKFORCE BACKGROUND SCREENING/VERIFICATION SYSTEMS	85
6.4	TECHNOLOGY/PRODUCT ROADMAP	85
6.5	PATENT ANALYSIS	86
6.5.1	PATENT PUBLICATION TRENDS FOR DRUG SCREENING MARKET	86
6.5.2	INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS	87
6.6	FUTURE APPLICATIONS	90
6.6.1	AI-ENABLED INTELLIGENT SCREENING AND RESULT INTERPRETATION	90
6.6.2	CONTINUOUS AND PREDICTIVE DRUG MONITORING APPLICATIONS	91
6.6.3	DECENTRALIZED, AT-HOME, AND POINT-OF-CARE SCREENING EXPANSION	91
6.6.4	INTEGRATED COMPLIANCE, FORENSIC, AND PUBLIC HEALTH INTELLIGENCE PLATFORMS	91
6.6.5	PERSONALIZED AND THERAPEUTIC DRUG SCREENING APPLICATIONS	92
6.7	IMPACT OF AI/GEN AI ON DRUG SCREENING MARKET	92
6.7.1	INTRODUCTION	92
6.7.2	MARKET POTENTIAL OF AI/GEN AI IN DRUG SCREENING MARKET	93
6.7.3	CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION	94
6.7.3.1	AI-driven transformation of preclinical toxicology screening at PathAI	94

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.7.4	IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS	95
6.7.4.1	Laboratory & toxicology operations	95
6.7.4.2	Laboratory information systems (LIS) & compliance infrastructure	95
6.7.4.3	Clinical care, workplace safety, and monitoring programs	96
	?	
6.7.5	USER READINESS AND IMPACT ASSESSMENT	96
6.7.5.1	User readiness	96
6.7.5.1.1	User A: Clinical, reference, and toxicology laboratories	96
6.7.5.1.2	User B: Healthcare providers, employers, and forensic agencies	96
6.7.5.2	Impact assessment	97
6.7.5.2.1	User A: Clinical, reference, and toxicology laboratories	97
6.7.5.2.1.1	Implementation	97
6.7.5.2.1.2	Impact	97
6.7.5.2.2	User B: Healthcare providers, employers, and forensic agencies	97
6.7.5.2.2.1	Implementation	97
6.7.5.2.2.2	Impact	97
7	CUSTOMER LANDSCAPE & BUYER BEHAVIOR	98
7.1	INTRODUCTION	98
7.2	DECISION-MAKING PROCESS	98
7.3	BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA	99
7.3.1	KEY STAKEHOLDERS IN BUYING PROCESS	99
7.3.2	BUYING CRITERIA	100
7.4	ADOPTION BARRIERS & INTERNAL CHALLENGES	101
7.5	UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES	101
7.5.1	UNMET NEEDS	102
7.5.2	END-USER EXPECTATIONS	103
7.6	MARKET PROFITABILITY	103
8	REGULATORY LANDSCAPE	105
8.1	REGIONAL REGULATIONS & COMPLIANCE	105
8.1.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	106
8.1.2	REGULATORY FRAMEWORK	109
8.1.2.1	North America	109
8.1.2.2	Europe	110
8.1.2.3	Asia Pacific	111
8.1.2.4	Latin America	111
8.1.2.5	Middle East & Africa	112
8.1.3	INDUSTRY STANDARDS	112
9	DRUG SCREENING MARKET, BY OFFERING	113
9.1	INTRODUCTION	114
9.2	SERVICES	114
9.2.1	WORKFORCE DECENTRALIZATION, PANEL COMPLEXITY, AND LITIGATION-READY TESTING TO DRIVE SUSTAINED MARKET GROWTH	114
9.2.2	LABORATORY TESTING SERVICES	116
9.2.2.1	Ability to ensure analytical rigor and compliance with regulatory standards to drive demand	116
9.2.3	ON-SITE TESTING SERVICES	117
9.2.3.1	Ability to deliver rapid, point-of-care screening solutions to drive market growth	117

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3 PRODUCTS 118
- 9.3.1 ANALYTICAL INSTRUMENTS MARKET, BY TYPE 120
 - 9.3.1.1 Breathalyzers 122
 - 9.3.1.1.1 Fuel-cell breathalyzers 123
 - 9.3.1.1.1.1 Extremely high accuracy, sensitivity, and reliability to drive demand for fuel-cell breathalyzers 123
 - 9.3.1.1.2 Semiconductor breathalyzers 124
 - 9.3.1.1.2.1 Lower prices of semiconductor breathalyzers to drive adoption 124
 - 9.3.1.1.3 Other breathalyzers 125
 - 9.3.1.2 Immunoassay analyzers 126
 - 9.3.1.2.1 Growing adoption of high-throughput immunoassay platforms to power modern toxicology 126
 - 9.3.1.3 Chromatography instruments 127
 - 9.3.1.3.1 Advantages such as precise, high-sensitivity analysis in forensic, clinical, and regulatory laboratories to fuel growth 127
 - 9.3.2 ANALYTICAL INSTRUMENTS MARKET, BY MODALITY 127
 - 9.3.2.1 Handheld breathalyzers 128
 - 9.3.2.1.1 Critical role in delivering fast, accurate, and portable alcohol screening to support market growth 128
 - 9.3.2.2 Benchtop breathalyzers 129
 - 9.3.2.2.1 Growing use of benchtop breathalyzers for drug detection analysis to drive growth 129
 - 9.3.3 RAPID TESTING DEVICES 130
 - 9.3.3.1 Urine testing devices 131
 - 9.3.3.1.1 Drug testing cups 133
 - 9.3.3.1.1.1 Reduced contact with urine sample to drive demand 133
 - 9.3.3.1.2 Dip cards 133
 - 9.3.3.1.2.1 Ability to provide qualitative results within minutes to propel market 133
 - 9.3.3.1.3 Drug testing cassettes 134
 - 9.3.3.1.3.1 Lower cost alternatives to drug testing cups and dip cards to boost adoption 134
 - 9.3.3.2 Oral fluid testing devices 135
 - 9.3.3.2.1 Rapid, non-invasive detection of recent drug use across workplace, clinical, and law enforcement settings to fuel growth 135
 - 9.3.4 CONSUMABLES 136
 - 9.3.4.1 Assay kits 137
 - 9.3.4.1.1 Rapid, cost-effective, and high-throughput screening across drug testing applications to drive market 137
 - 9.3.4.2 Sample collection devices 138
 - 9.3.4.2.1 Reliable, tamper-resistant, and versatile drug testing across settings to support growth 138
 - 9.3.4.3 Calibrators & controls 139
 - 9.3.4.3.1 Ability to verify accuracy, precision, and reliability of screening and confirmatory test results to drive growth 139
 - 9.3.4.4 Other consumables 140
 - 10 DRUG SCREENING MARKET, BY SAMPLE TYPE 142
 - 10.1 INTRODUCTION 143
 - 10.2 URINE SAMPLES 143
 - 10.2.1 RECENT ADVANCES TO STRENGTHEN ACCURACY AND RELIABILITY IN URINE DRUG TESTING 143
 - 10.3 BREATH SAMPLES 145
 - 10.3.1 BREATH ALCOHOL TESTS TO REGISTER WIDE USAGE IN WORKPLACE TESTING AND LAW ENFORCEMENT APPLICATIONS 145
 - 10.4 ORAL FLUID SAMPLES 146
 - 10.4.1 NON-INVASIVE SAMPLE COLLECTION AND LOW CHANCE OF ADULTERATION TO SUPPORT USAGE OF ORAL FLUID SAMPLES 146
 - 10.5 HAIR SAMPLES 147
 - 10.5.1 ABILITY OF HAIR SAMPLES TO PROVIDE INSIGHTS INTO LONG-TERM DRUG USE TO BOOST MARKET 147

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.6	OTHER SAMPLES	149
11	DRUG SCREENING MARKET, BY DRUG TYPE	150
11.1	INTRODUCTION	151
11.2	CANNABIS	151
11.2.1	GROWING CANNABIS USE AND REGULATORY COMPLEXITY TO DRIVE SUSTAINED DEMAND FOR DRUG SCREENING SOLUTIONS	151
11.3	ALCOHOL	153
11.3.1	REGULATORY ENFORCEMENT AND TECHNOLOGY INNOVATION TO STRENGTHEN ALCOHOL SCREENING ADOPTION	153
11.4	COCAINE	154
11.4.1	SHIFT TOWARD RAPID, DEFENSIBLE DETECTION TO POSITION COCAINE AS PRIORITY DRUG IN MODERN SCREENING PANELS	154
11.5	OPIOIDS	156
11.5.1	EXPANDED OPIOID PANELS AND ADVANCED CONFIRMATORY TECHNOLOGIES TO REINFORCE OPIOID SCREENING AS HIGH PRIORITY	156
11.6	AMPHETAMINES & METHAMPHETAMINES	157
11.6.1	ADVANCED ANALYTICS AND DIFFERENTIATION TESTING TO REDEFINE AMPHETAMINE & METHAMPHETAMINE DETECTION	157
11.7	OTHER DRUGS	159
	?	
12	DRUG SCREENING MARKET, BY END USER	161
12.1	INTRODUCTION	162
12.2	DRUG TESTING LABORATORIES	162
12.2.1	ADVANCED ANALYTICS, AUTOMATION, AND EXPANDING FORENSIC AND CLINICAL DEMAND TO DRIVE MARKET GROWTH	162
12.3	WORKPLACES	164
12.3.1	RISING NUMBER OF DRUG ABUSE CASES TO INCREASE WORKPLACE TESTING	164
12.4	CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES	165
12.4.1	HIGH SUBSTANCE-USE PREVALENCE AND DUI RISKS TO DRIVE MANDATORY DRUG & ALCOHOL TESTING	165
12.5	HOSPITALS	166
12.5.1	RISING EMERGENCY ADMISSIONS, OPIOID OVERDOSES, AND PATIENT SAFETY MANDATES TO DRIVE STRONG DEMAND	166
12.6	DRUG TREATMENT CENTERS	168
12.6.1	RISING ADOPTION OF MEDICATION-ASSISTED TREATMENT, RELAPSE MONITORING, AND FENTANYL DETECTION TO DRIVE DEMAND	168
12.7	INDIVIDUAL USERS	169
12.7.1	GROWING SELF-MONITORING, HOME TESTING, AND RECOVERY ACCOUNTABILITY TO EXPANDING INDIVIDUAL USE OF SCREENING	169
12.8	PAIN MANAGEMENT CENTERS	170
12.8.1	OPIOID PRESCRIBING OVERSIGHT AND PATIENT SAFETY MANDATES TO DRIVE INCREASED DRUG SCREENING	170
12.9	SCHOOLS & COLLEGES	171
12.9.1	MODERN TESTING AND AWARENESS PROGRAMS TO STRENGTHEN DRUG ABUSE PREVENTION IN SCHOOLS & COLLEGES	171
12.10	OTHER END USERS	173
13	DRUG SCREENING MARKET, BY REGION	175
13.1	INTRODUCTION	176
13.2	NORTH AMERICA	177
13.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	177
13.2.2	US	184
13.2.2.1	Regulatory enforcement and substance use prevalence drive drug screening market in US	184
13.2.3	CANADA	190
13.2.3.1	Public health surveillance, consumption trends, and enforcement & technological advancements to drive market	190

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.3 EUROPE 196
 - 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 196
 - 13.3.2 GERMANY 202
 - 13.3.2.1 Strengthening drug screening adoption through public health policy and technological modernization to support market growth 202
 - ?
 - 13.3.3 FRANCE 208
 - 13.3.3.1 Regulatory enforcement, transport safety, and forensic modernization to shape drug screening market 208
 - 13.3.4 UK 213
 - 13.3.4.1 Community-embedded testing, criminal justice demand, and real-time drug surveillance to shape UK drug screening market 213
 - 13.3.5 ITALY 219
 - 13.3.5.1 Strengthening drug screening market through roadside enforcement and analytical innovation & institutional capacity 219
 - 13.3.6 SPAIN 225
 - 13.3.6.1 Expanding drug screening adoption through road safety programs to drive market growth 225
 - 13.3.7 REST OF EUROPE 230
- 13.4 ASIA PACIFIC 235
 - 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 236
 - 13.4.2 CHINA 243
 - 13.4.2.1 Synthetic drug control and pharmaceutical innovation to drive drug screening market growth 243
 - 13.4.3 JAPAN 248
 - 13.4.3.1 Japan's aging population and advanced digital infrastructure to drive rapid adoption 248
 - 13.4.4 INDIA 253
 - 13.4.4.1 Alcohol dominance, opioid misuse, and India's role as global pharmaceutical hub to drive drug screening market growth 253
 - 13.4.5 AUSTRALIA 259
 - 13.4.5.1 Harm-reduction policy, workplace safety regulation, and roadside testing to drive drug screening market 259
 - 13.4.6 SOUTH KOREA 264
 - 13.4.6.1 Zero-tolerance drug policy, mandatory military service, and forensic-grade testing to shape drug screening market 264
 - 13.4.7 REST OF ASIA PACIFIC 269
- 13.5 LATIN AMERICA 274
 - 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 274
 - 13.5.2 BRAZIL 280
 - 13.5.2.1 Brazil's drug screening market to expand amid road safety mandates, substance-use burden, and regulatory enforcement 280
 - 13.5.3 MEXICO 286
 - 13.5.3.1 Mexico's drug screening market shaped by methamphetamine prevalence, cross-border labor dynamics, and public safety enforcement 286
 - 13.5.4 REST OF LATIN AMERICA 291
- 13.6 MIDDLE EAST & AFRICA 296
 - 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 297
 - 13.6.2 GCC COUNTRIES 303
 - 13.6.2.1 Saudi Arabia 309
 - 13.6.2.1.1 Public safety, diagnostic modernization, and evolving consumption patterns to boost market 309
 - 13.6.2.2 UAE 314
 - 13.6.2.2.1 Integrated safety enforcement, workplace testing, and diagnostic modernization to expand market in UAE 314
 - 13.6.2.3 Rest of GCC Countries 319

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.6.3 SOUTH AFRICA 324
 - 13.6.3.1 Rising substance use, workplace risk management, and advanced screening capabilities to fuel market growth 324
- 13.6.4 REST OF MIDDLE EAST & AFRICA 329
- 14 COMPETITIVE LANDSCAPE 335
 - 14.1 OVERVIEW 335
 - 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 335
 - 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG SCREENING MARKET 335
 - 14.3 REVENUE ANALYSIS, 2020-2024 337
 - 14.4 MARKET SHARE ANALYSIS, 2024 338
 - 14.5 BRAND COMPARISON 341
 - 14.6 COMPANY VALUATION & FINANCIAL METRICS 342
 - 14.6.1 FINANCIAL METRICS 342
 - 14.6.2 COMPANY VALUATION 342
 - 14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 343
 - 14.7.1 STARS 343
 - 14.7.2 EMERGING LEADERS 343
 - 14.7.3 PERVASIVE PLAYERS 343
 - 14.7.4 PARTICIPANTS 344
 - 14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 345
 - 14.7.5.1 Company footprint 345
 - 14.7.5.2 Region footprint 346
 - 14.7.5.3 Offering footprint 347
 - 14.7.5.4 Sample type footprint 348
 - 14.7.5.5 Drug type footprint 349
 - 14.7.5.6 End-user footprint 350
 - 14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 351
 - 14.8.1 PROGRESSIVE COMPANIES 351
 - 14.8.2 RESPONSIVE COMPANIES 351
 - 14.8.3 DYNAMIC COMPANIES 351
 - 14.8.4 STARTING BLOCKS 351
 - 14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 353
 - 14.8.5.1 Detailed list of key startups/SMEs 353
 - 14.8.5.2 Competitive benchmarking of startups/SMEs 354
 - ?
 - 14.9 COMPETITIVE SCENARIO 355
 - 14.9.1 PRODUCT LAUNCHES & ENHANCEMENTS 355
 - 14.9.2 DEALS 356
 - 14.9.3 OTHER DEVELOPMENTS 357
- 15 COMPANY PROFILES 358
 - 15.1 KEY PLAYERS 358
 - 15.1.1 LABCORP 358
 - 15.1.1.1 Business overview 358
 - 15.1.1.2 Products & services offered 359
 - 15.1.1.3 Recent developments 360
 - 15.1.1.3.1 Deals 360
 - 15.1.1.4 MnM view 361
 - 15.1.1.4.1 Key strengths 361

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1.1.4.2 Strategic choices 361
- 15.1.1.4.3 Weaknesses & competitive threats 361
- 15.1.2 QUEST DIAGNOSTICS INCORPORATED 362
- 15.1.2.1 Business overview 362
- 15.1.2.2 Products & services offered 363
- 15.1.2.3 Recent developments 364
- 15.1.2.3.1 Product & service launches 364
- 15.1.2.3.2 Deals 364
- 15.1.2.4 MnM view 365
- 15.1.2.4.1 Key strengths 365
- 15.1.2.4.2 Strategic choices 366
- 15.1.2.4.3 Weaknesses & competitive threats 366
- 15.1.3 ABBOTT 367
- 15.1.3.1 Business overview 367
- 15.1.3.2 Products & services offered 369
- 15.1.3.3 MnM view 371
- 15.1.3.3.1 Key strengths 371
- 15.1.3.3.2 Strategic choices 371
- 15.1.3.3.3 Weaknesses & competitive threats 371
- 15.1.4 ORASURE TECHNOLOGIES INC. 372
- 15.1.4.1 Business overview 372
- 15.1.4.2 Products & services offered 374
- 15.1.4.3 Recent developments 374
- 15.1.4.3.1 Deals 374
- 15.1.4.4 MnM view 375
- 15.1.4.4.1 Key strengths 375
- 15.1.4.4.2 Strategic choices 375
- 15.1.4.4.3 Weaknesses & competitive threats 375
- 15.1.5 ALFA SCIENTIFIC DESIGNS INC. 376
- 15.1.5.1 Business overview 376
- 15.1.5.2 Products & services offered 377
- 15.1.5.3 MnM view 378
- 15.1.5.3.1 Key strengths 378
- 15.1.5.3.2 Strategic choices 378
- 15.1.5.3.3 Weaknesses & competitive threats 378
- 15.1.6 THERMO FISHER SCIENTIFIC INC. 379
- 15.1.6.1 Business overview 379
- 15.1.6.2 Products & services offered 381
- 15.1.6.3 Recent developments 384
- 15.1.6.3.1 Product developments 384
- 15.1.6.3.2 Deals 385
- 15.1.7 DRAGERWERK AG & CO. KGAA 386
- 15.1.7.1 Business overview 386
- 15.1.7.2 Products & services offered 388
- 15.1.7.3 Recent developments 388
- 15.1.7.3.1 Product launches 388
- 15.1.8 LIFELOC TECHNOLOGIES, INC. 389

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.1.8.1	Business overview	389
15.1.8.2	Products & services offered	390
15.1.8.3	Recent developments	392
15.1.8.3.1	Other developments	392
15.1.9	MPD INC.	393
15.1.9.1	Business overview	393
15.1.9.2	Products & services offered	394
15.1.10	OMEGA LABORATORIES, INC.	395
15.1.10.1	Business overview	395
15.1.10.2	Products & services offered	396
15.1.10.3	Recent developments	396
15.1.10.3.1	Service launches	396
15.1.10.3.2	Deals	397
15.1.10.3.3	Other developments	397
15.1.11	PREMIER BIOTECH, INC.	398
15.1.11.1	Business overview	398
15.1.11.2	Products & services offered	399
15.1.11.3	Recent developments	400
15.1.11.3.1	Deals	400
15.1.12	PSYCHEMEDICS CORPORATION	401
15.1.12.1	Business overview	401
15.1.12.2	Products & services offered	402
15.1.12.3	Recent developments	403
15.1.12.3.1	Product launches & enhancements	403
15.1.12.3.2	Other developments	404
15.1.13	F. HOFFMANN-LA ROCHE LTD.	405
15.1.13.1	Business overview	405
15.1.13.2	Products & services offered	407
15.1.13.3	Recent developments	408
15.1.13.3.1	Deals	408
15.1.14	SHIMADZU CORPORATION	409
15.1.14.1	Business overview	409
15.1.14.2	Products & services offered	411
15.1.14.3	Recent developments	412
15.1.14.3.1	Product launches	412
15.1.14.3.2	Deals	413
15.1.15	SIEMENS HEALTHINEERS AG	414
15.1.15.1	Business overview	414
15.1.15.2	Products & services offered	416
15.1.15.3	Recent developments	417
15.1.15.3.1	Product launches	417
15.1.15.3.2	Deals	417
15.1.16	BIO-RAD LABORATORIES, INC.	419
15.1.16.1	Business overview	419
15.1.16.2	Products & services offered	421
15.1.16.3	Recent developments	422
15.1.16.3.1	Product enhancements	422

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1.16.3.2 Deals 422
- 15.2 OTHER PLAYERS 424
 - 15.2.1 CAREHEALTH AMERICA CORP. 424
 - 15.2.2 ACCUSOURCEHR, INC. 425
 - 15.2.3 CORDANT HEALTH SOLUTIONS 426
 - 15.2.4 ADVACARE PHARMA 427
 - 15.2.5 ACM GLOBAL LABORATORIES 428
 - 15.2.6 MILLENNIUM HEALTH 429
 - 15.2.7 CLINICAL REFERENCE LABORATORY, INC. 430
 - 15.2.8 INTOXIMETERS 431
 - 15.2.9 INTOXALOCK 432
- 16 RESEARCH METHODOLOGY 433
 - 16.1 RESEARCH APPROACH 433
 - 16.1.1 SECONDARY RESEARCH 433
 - 16.1.1.1 Key data from secondary sources 434
 - 16.1.2 PRIMARY RESEARCH 435
 - 16.1.2.1 Primary sources 435
 - 16.1.2.2 Key data from primary sources 436
 - 16.1.2.3 Breakdown of primaries 437
 - 16.1.2.4 Insights from primary experts 438
 - 16.2 RESEARCH METHODOLOGY DESIGN 438
 - 16.3 MARKET SIZE ESTIMATION 439
 - 16.4 MARKET BREAKDOWN & DATA TRIANGULATION 444
 - 16.5 MARKET SHARE ESTIMATION 444
 - 16.6 STUDY ASSUMPTIONS 445
 - 16.7 RESEARCH LIMITATIONS 445
 - 16.7.1 METHODOLOGY-RELATED LIMITATIONS 445
 - 16.8 RISK ASSESSMENT 446
- 17 APPENDIX 447
 - 17.1 DISCUSSION GUIDE 447
 - 17.2 KNOWLEDGESTORE: MARKETSDMARKETS' SUBSCRIPTION PORTAL 452
 - 17.3 CUSTOMIZATION OPTIONS 454
 - 17.4 RELATED REPORTS 454
 - 17.5 AUTHOR DETAILS 455

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Drug Screening Market by Offering (On-site Testing, Rapid Testing (Urine, Oral), Analytical (Breathalyzer, Immunoassay, Chromatography)), Sample (Blood, Urine, Hair), Drug (Cannabis, Alcohol), End User (Workplace, Law, Hospitals) - Global Forecast to 2030

Market Report | 2026-02-13 | 456 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code*

Country*

Date

2026-03-16

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com